SG Americas Securities LLC Takes $59,000 Position in Accuray Incorporated (NASDAQ:ARAY)

SG Americas Securities LLC acquired a new position in Accuray Incorporated (NASDAQ:ARAY) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 32,820 shares of the medical equipment provider’s stock, valued at approximately $59,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its stake in shares of Accuray by 13.3% during the second quarter. The Manufacturers Life Insurance Company now owns 44,936 shares of the medical equipment provider’s stock worth $82,000 after buying an additional 5,273 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Accuray during the 2nd quarter worth $30,000. Armistice Capital LLC bought a new stake in shares of Accuray during the 2nd quarter valued at $910,000. Hsbc Holdings PLC lifted its stake in shares of Accuray by 55.1% in the 2nd quarter. Hsbc Holdings PLC now owns 101,683 shares of the medical equipment provider’s stock valued at $180,000 after purchasing an additional 36,108 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Accuray by 0.3% in the 2nd quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock worth $5,118,000 after purchasing an additional 7,500 shares during the last quarter. 64.08% of the stock is owned by institutional investors.

Accuray Stock Up 6.9 %

Shares of Accuray stock opened at $1.87 on Tuesday. Accuray Incorporated has a 12 month low of $1.40 and a 12 month high of $3.05. The business has a fifty day simple moving average of $1.96 and a 200 day simple moving average of $1.86. The company has a quick ratio of 0.95, a current ratio of 1.66 and a debt-to-equity ratio of 3.65. The stock has a market cap of $185.59 million, a PE ratio of -8.50 and a beta of 1.39.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported $0.03 EPS for the quarter, meeting analysts’ consensus estimates of $0.03. Accuray had a negative return on equity of 33.65% and a negative net margin of 3.48%. The company had revenue of $134.29 million during the quarter, compared to analysts’ expectations of $122.80 million. During the same period in the prior year, the business posted ($0.03) EPS. Research analysts predict that Accuray Incorporated will post -0.01 EPS for the current year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.